Biomarker · Circulating tumor DNA
Circulating tumor DNA (ctDNA)
Tumor-derived DNA fragments in plasma analyzed by sequencing or PCR; used as a specimen for genotyping (mutations, fusions, MSI, TMB) and studied as a prognostic marker for minimal residual disease.
CI-BIO-00000031NCIt C113243
Also calledctDNA · liquid biopsy · cell-free tumor DNA · plasma genotyping
Derived
Associated cancers (0)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
Data not yet available
Derived
Drugs with predictive evidence (0)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
Data not yet available
Curated evidence
Predictive evidence items (0)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
Data not yet available
Regulatory
Approvals mentioning the linked drugs (1)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-04
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260908-000001
Clinical trials
Active trials (0)
Data not yet available
Literature
Linked publications (0)
Data not yet available